Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...
Researchers at the Indian Institute of Science (IISc), with collaborators from the Institute of Mathematical Sciences (IMSc), ...
6hon MSN
New method reveals how mutations drive transthyretin amyloidosis and guides precision drug design
An international research team reveals new molecular mechanisms associated with pathogenic mutations in the protein ...
Scientists have made a discovery that helps explain why humans and animals are so susceptible to contracting tuberculosis (TB ...
Researchers identified a key molecule that highlights how the immune system is linked to the release of dopamine.
Tumor immunotherapy has rapidly emerged as a cornerstone in oncology, revolutionizing the treatment landscape for patients with advanced malignancies.
News-Medical.Net on MSN
Targeting IDO1 for cancer: Novel degraders show promise in preclinical studies
Cancer cells employ a variety of strategies to evade the immune system, and modern immunotherapies aim precisely at these ...
The field of cancer immunology has witnessed dramatic progress with the advent of immunotherapies targeting the tumor immune microenvironment (TIME).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback